Published on 16/11/2025

Coding for Hybrid and DCT Studies With High Volumes of Free Text

In an era where clinical trials increasingly leverage technology to gather data, the need for efficient data management systems becomes paramount. Hybrid and decentralized clinical trials (DCTs) particularly challenge data management practices due to their multifaceted data sources, including a significant amount of free text data. This article provides a step-by-step guide aimed at clinical operations, regulatory affairs, and medical affairs professionals involved in the coding of clinical trial data management, specifically focusing on medical coding using MedDRA and WHO-DD classification systems.

Understanding the Importance of Medical Coding in Clinical Trials

Medical coding is critical for the standardization of clinical trial data. It ensures that data can be effectively analyzed, interpreted, and communicated across various stakeholders. In trials such as the adaura clinical trial, where high volumes of free-text data are prevalent, robust coding mechanisms are essential. Coding also aids in reporting adverse events, allowing for consistent regulatory submissions in compliance with ICH-GCP guidelines and regulatory authorities such as the FDA and EMA.

Using standardized medical terminology helps mitigate discrepancies and enhances the quality and integrity of clinical data. Medical coding facilitates the integration of safety data and can improve the overall efficacy of clinical trial reporting. Furthermore, it ensures compliance with relevant regulatory standards. For professionals in clinical operations, understanding the nuances of medical coding is therefore vital.

Step 1: Familiarize Yourself with Medical Coding Systems

The first step in the coding process is to familiarize yourself with the two predominant medical coding systems: MedDRA (Medical Dictionary for Regulatory Activities) and WHO-DD (World Health Organization Drug Dictionary). Each system offers distinct advantages and applications in clinical trial data management.

• MedDRA: Used primarily for coding adverse events, symptoms, and conditions in clinical trials. MedDRA is a highly detailed terminology encompassing a wide array of medical concepts.
• WHO-DD: This dictionary is used for drug-related terms, including indications, side effects, and therapeutic areas. WHO-DD is particularly useful for drug safety reporting.

Understanding the structure and hierarchy of these coding systems is crucial in streamlining the coding process. Familiarity with the terms, preferred terminology, and acceptable synonyms will enable accurate data classification.

Step 2: Establish a Coding Process for Hybrid and DCT Studies

The establishment of a standardized coding process is key to managing high volumes of free-text data effectively. Here are the essential steps for developing this process:

Defining the Coding Workflow

Outline a clear workflow that delineates responsibilities among team members. This workflow should include steps for data extraction, coding, quality control, and cross-validation. Implementing a systematic workflow can significantly enhance the consistency and reliability of coding outcomes.

Develop Coding Guidelines

Create comprehensive coding guidelines tailored to the needs of your clinical trial. Include definitions, examples, and flowcharts that depict how to deal with common terms and phrases in free-text data. These guidelines should also address how to handle synonyms and alternative terminologies across MedDRA and WHO-DD.

Utilize Coding Software Tools

Incorporate coding software tools that facilitate the coding process. Many organizations use Electronic Data Capture (EDC) systems or specialized coding software equipped with robust algorithms that can suggest codes for textual data based on predefined rules which immensely aids in large volume settings typical of hybrid and DCTs.

Step 3: Implement Training and Development

Training is crucial for ensuring that all team members involved in the coding process are well-versed in the coding systems and the procedures established. Here are several components to consider:

Initial Training Sessions

Conduct initial training sessions that cover the fundamentals of both MedDRA and WHO-DD coding systems, including usage, phrasing variations, and exception handling. Utilize real-life case studies to illustrate coding challenges encountered in previous trials.

Ongoing Education and Reference Materials

Provide access to reference materials such as manuals, online resources, and databases that team members can consult. It’s essential to encourage ongoing education as coding systems evolve and new terms are regularly introduced. This continuous learning approach ensures that coding remains compliant with regulatory standards.

Feedback Mechanism

Establish feedback mechanisms to address queries, provide clarification, and promote knowledge sharing among team members. Regular team meetings can help maintain coding quality and promote best practices across the organization.

Step 4: Quality Control in Medical Coding

Establishing quality control measures is critical to ensuring the integrity and accuracy of data derived from hybrid and decentralized clinical trials.

Data Review and Validation

Implement a two-tiered review mechanism wherein coded data undergoes quality checks by experienced coders. This process may include metrics for evaluating coding performance and accuracy. Random sampling techniques can also be employed to ascertain coding consistency.

Utilize Automated Tools for Quality Assurance

Leverage automated tools and scripts to perform consistency checks and identify outliers in coding. Machine learning algorithms can assist with natural language processing (NLP) to interpret free text from clinical narratives and reduce human error.

Periodic Audits

Conduct regular audits of the coded datasets to ensure compliance with internal guidelines and applicable regulatory requirements. Engaging external auditors helps validate the coding quality and uncover areas for improvement.

Step 5: Reporting and Communication with Regulatory Authorities

Once the coding process is complete, reporting outcomes to stakeholders, including regulatory authorities, is the final step。

Standardized Terminology for Reporting

Adhere to standardized terms from MedDRA and WHO-DD when preparing reports for regulatory submissions. Consistency in terminology makes it easier for regulatory bodies to interpret safety and efficacy data presented in the submissions.

Efficient Communication Channels

Establish clear communication channels between the coding teams and regulatory affairs specialists. Prompt and transparent communication ensures that any discrepancies or queries can be addressed expeditiously, which is crucial in adhering to regulatory timelines.

Post-Submission Follow-up

After submitting reports to regulatory authorities, be prepared for follow-up queries. Maintain a detailed log of coding decisions made throughout the trial process, as this documentation will aid in justifying any responses needed during regulatory inspections or queries.

Conclusion

As the landscape of clinical trials evolves with the adoption of hybrid and decentralized models, the strategies for managing and coding clinical trial data must keep pace. By implementing the steps outlined in this guide, clinical operations, regulatory affairs, and medical affairs professionals can enhance their capabilities in handling high volumes of free text data using coding systems like MedDRA and WHO-DD. Through meticulous preparation, training, quality control, and transparent communication, organizations can improve the accuracy and reliability of their clinical trial data, ensuring successful outcomes in adherence with ICH-GCP and regulatory requirements.